2025-12-21 - Analysis Report
Okay, let's break down the analysis of Teladoc Health Inc. (TDOC).

**1) Return Rate Comparison & Alpha/Beta Analysis**

*   **Company Overview:** Teladoc Health Inc. is a telehealth and virtual healthcare company.
*   **Return Rate Comparison:**
    *   TDOC Cumulative Return: -64.26%
    *   VOO (S&P 500) Cumulative Return: 101.92%
    *   Divergence: -164.2 (Relative Divergence: 0.5)

    **Analysis:** TDOC has significantly underperformed the S&P 500, with a large negative divergence.  The relative divergence of 0.5 suggests that the current divergence is near the bottom end of its historical range.

*   **Alpha, Beta, and Performance Analysis (Table):**

    | Year       | CAGR     | MDD     | Alpha   | Beta   | Cap(B) |
    |------------|----------|----------|---------|--------|--------|
    | 2015-2017  | 77.0%    | 70.4%    | 51.0%   | -0.1   | 6.2    |
    | 2016-2018  | 101.0%   | 69.4%    | 86.0%   | -0.1   | 8.8    |
    | 2017-2019  | 141.0%   | 73.8%    | 118.0%  | 0.3    | 14.9   |
    | 2018-2020  | 105.0%   | 80.9%    | 81.0%   | 0.3    | 35.5   |
    | 2019-2021  | -78.0%   | 80.9%    | -125.0%  | 0.3    | 16.3   |
    | 2020-2022  | -252.0%  | 85.9%    | -251.0%  | -0.9   | 4.2    |
    | 2021-2023  | -315.0%  | 85.9%    | -316.0%  | -1.8   | 3.8    |
    | 2022-2024  | -93.0%   | 85.9%    | -113.0%  | -1.9   | 1.6    |
    | 2023-2025  | -35.0%   | 81.6%    | -101.0%  | -0.8   | 1.3    |

    **Analysis:** The table reveals a dramatic shift in TDOC's performance.
    *   **Early Growth (2015-2020):** High CAGR, positive Alpha, and relatively low Beta (close to 0). This suggests strong outperformance compared to the market and low sensitivity to market movements.
    *   **Recent Struggles (2019-2025):**  Negative CAGR, significantly negative Alpha, and increasingly negative Beta.  This indicates severe underperformance, high idiosyncratic risk, and a potential inverse correlation with the market.  The high MDD (Maximum Drawdown) values reflect the substantial losses experienced. The market cap has significantly declined.

**2) Recent Stock Price Fluctuations**

*   Close Price: 7.23
*   Last Market Data: {'price': 7.23, 'previousClose': 7.14, 'change': 1.26}
*   5-day SMA: 7.274
*   20-day SMA: 7.4435
*   60-day SMA: 7.9054

    **Analysis:** The stock price is below all three Simple Moving Averages (SMAs), indicating a short-term downtrend. The price has recently risen to 7.23 from 7.14 (previous close) with 1.26 change, indicating a possible rebound.

**3) Market Risk Indicator, RSI, PPO, Hybrid Signal, Recent Divergence Change, and Expected Return**

*   Market Risk Indicator (MRI): 0.7 (Medium Investment)
*   RSI: 39.19 (Approaching oversold, but not quite there)
*   PPO: -0.1761 (Slightly negative momentum)
*   Hybrid Signal: cash_0%_Buy 100% of cash (132 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   Recent (20 days) relative divergence change: 0.0 (단기하락 - short-term decline)
*   Expected Return (%): -10274.4%

    **Analysis:**
    *   The MRI suggests a "Medium Investment" risk level, but this should be viewed with caution given the other indicators.
    *   The RSI is below 50, suggesting bearish momentum, though not yet in oversold territory.
    *   The PPO indicates slightly negative momentum.
    *   Recent relative divergence change indicates recent short-term decline
    *   The extremely negative Expected Return suggests very high risk and potential for continued underperformance.  This is a highly concerning signal.
    *   Hybrid signal shows a buy (100% cash) suggestion based on MRI: 0.9.

**4) Recent News & Significant Events**

*   **[2025-11-25] Assessing Valuation After Recent Short-Term Share Price Rebound:** This suggests the recent price increase might be a temporary correction rather than a sustained recovery.
*   **[2025-12-18] Receives Consensus Rating of "Hold" from Brokerages:** This indicates analysts are generally neutral on the stock.
*   **[2025-12-03 & 2025-12-04] Insider Sales:** Insider selling is generally considered a negative signal, suggesting that those with the most knowledge of the company's prospects are selling their shares.
*   **[2025-12-18] Responsive Playbooks and the TDOC Inflection:** The title indicates a potential turning point for the stock, but the content needs to be examined to evaluate the validity of the claim.
*   **[2025-11-03] Is This Beaten-Down Stock Finally on the Road to Recovery?:**  The question mark implies uncertainty about a true recovery.

**Analysis:** The news is mixed. While there's some talk of rebound potential, the "Hold" rating and, more importantly, the insider sales are concerning.

**4-2) Analyst Opinions**

*   Consensus: Hold (Mean: 2.67)
*   Target Price: 9.18 (Avg), 12.00 (High), 7.00 (Low)

**Analysis:** The consensus "Hold" rating reflects a neutral stance. The average target price of $9.18 is slightly above the current price, suggesting some potential upside, but the range is wide ($7.00 - $12.00), indicating uncertainty. The lack of recent rating changes provides no new insight.

**5) Recent Earnings Analysis**

| Date       | EPS   | Revenue      |
|------------|-------|--------------|
| 2025-10-30 | -0.28 | 0.63 B$      |
| 2025-07-30 | -0.19 | 0.63 B$      |
| 2025-05-01 | -0.53 | 0.63 B$      |
| 2024-10-31 | -0.19 | 0.64 B$      |
| 2025-10-30 | -0.19 | 0.64 B$      |

**Analysis:**
*   Teladoc continues to operate at a loss. While EPS has fluctuated, it consistently remains negative.
*   Revenue has remained relatively flat around $0.63-0.64 billion per quarter.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|----------------|
| 2025-09-30   | $0.63B     | 70.12%         |
| 2025-06-30   | $0.63B     | 69.85%         |
| 2025-03-31   | $0.63B     | 68.73%         |
| 2024-12-31   | $0.64B     | 70.50%         |
| 2024-09-30   | $0.64B     | 71.94%         |

**Capital and Profitability:**

| Quarter      | Equity      | ROE       |
|--------------|-------------|-----------|
| 2025-09-30   | $1.39B      | -3.56%    |
| 2025-06-30   | $1.42B      | -2.30%    |
| 2025-03-31   | $1.43B      | -6.52%    |
| 2024-12-31   | $1.49B      | -3.25%    |
| 2024-09-30   | $1.51B      | -2.21%    |

**Analysis:**
*   Revenue remains stable, but profitability (as measured by ROE) is negative.
*   Equity has been decreasing gradually, indicating that the company is losing money.
*   Profit margins are relatively high, which suggests the problem isn't revenue generation, but rather high operating costs, interest expense, or some other factor impacting net income.

**7) Comprehensive Analysis (Summary)**

Teladoc Health Inc. (TDOC) faces significant challenges. While the company showed promise in the past, recent performance has been poor.

*   **Negative Performance:** TDOC has significantly underperformed the S&P 500, with a large negative divergence. The negative Alpha and Beta values highlight this underperformance and suggest increased risk.
*   **Financial Weakness:** The company is not profitable, with negative EPS and ROE. Revenue has been flat.
*   **Mixed Signals:** Recent price increases may be a temporary rebound, but insider selling raises concerns about the company's future prospects. The "Hold" analyst consensus reflects a neutral outlook. The extremely negative expected return is a major red flag.

**Overall Conclusion:** Based on the data provided, investing in TDOC appears risky. The company's negative financial performance, underperformance compared to the market, and negative sentiment from insiders and some indicators suggest caution. Further in-depth research into Teladoc's specific challenges and potential turnaround strategies is necessary before considering an investment.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.